Enspryng (satralizumab) is superior to conventional immunosuppressive therapies in reducing the risk of relapses in people with neuromyelitis optica spectrum disorder (NMOSD) for up to three years, and with a comparable safety profile, according to a real-world study. Similar results were obtained when analyzing data only from NMOSD…
Enspryng
Long-term use of the approved therapy Enspryng (satralizumab) safely and effectively prevented relapses in people with neuromyelitis optica spectrum disorder (NMOSD) who have antibodies against aquaporin-4 (AQP4). That’s according to up to 8.8 years of pooled data from two placebo-controlled Phase 3 clinical trials — SAkuraStar (NCT02073279) and …
Treatment with Enspryng (satralizumab) allows nearly all neuromyelitis optica spectrum disorder (NMOSD) patients to remain free of relapses after six months, with many reducing their use of corticosteroids and other immunosuppressants. Nearly one-third of patients were able to stop corticosteroids, which can cause serious side effects when used…
Switching from Soliris (eculizumab) to Enspryng (satralizumab) is a safe and effective approach for neuromyelitis optica spectrum disorder (NMOSD) patients testing positive for antibodies against the AQP4 protein. That’s according to data from five patients in the U.S. who switched treatments due to either preference for route…
Most neuromyelitis optica spectrum disorder (NMOSD) patients who start taking Enspryng (satralizumab) remain free of relapses for at least a year, with some being able to stop treatment with oral glucocorticoids, according to a study of real-world data. The findings are consistent with those of SAkuraStar (NCT02073279)…
An international team of experts has published evidence-based recommendations for how to best treat people with neuromyelitis optica spectrum disorder (NMOSD) who are positive for aquaporin-4 immunoglobulin G (AQP4-IgG), the most common type of disease-driving antibody. The consensus statements were described in the study “International Delphi…
The past few years have been challenging for me, my family, and especially my youngest daughter, Bella, who in 2017 was diagnosed at 9 years old with neuromyelitis optica spectrum disorder (NMOSD). At the time, the best course of therapy recommended by Bella’s neurologist was Rituxan…
A global Phase 4 clinical trial of Enspryng (satralizumab), approved to treat the most common form of neuromyelitis optica spectrum disorder (NMOSD), is enrolling newly diagnosed and other patients who could not or did not take part in Phase 3 trials of the therapy. In addition to people new…
What do you do when you’ve run out of choices? That’s where I found myself in May 2020. After living attack-free for 10 years, I was stunned when I found myself dealing with a surprise neuromyelitis optica (NMO) attack. It wasn’t until the end of that summer that I…
Astrocytes, star-shaped cells found around nerve cells, make an inflammation driver of neuromyelitis optica spectrum disorder (NMOSD) called interleukin-6 (IL-6) in part by gearing up a chain of reactions involving nuclear factor kappa B, or NF-kappaB, according to a study in rat cells. Researchers also observed that by blocking…
Recent Posts
- Grieving how NMOSD has left me uncomfortable in my own skin
- Enspryng outperforms standard immunosuppressants in NMOSD study
- Slow and steady: I’m ditching big resolutions and easing into a new year
- Late-onset NMOSD responds better to newer, highly effective therapies
- New biomarker may help gauge disease severity in NMOSD
- The longest night of the year offers hope of brighter days with NMOSD
- Advanced plasma exchange therapy effectively eases NMOSD attacks
- Reaffirming that access to healthcare is a human right
- Brain, spinal cord shrinkage linked to distinct NMOSD outcomes: Study
- Reflecting on what I’m grateful for softens the edges of NMOSD